Ofev

Content

SLOW THE PATH OF IPF PROGRESSION FOR YOUR MEMBERS

OFEV (nintedanib)—for the treatment of idiopathic pulmonary fibrosis (IPF)

• OFEV has been studied in approximately 1200-people with IPF across 3 clinical trials
• OFEV:
- Reduced the decline of lung function, measured by annual rate of FVC decline, by approximately 50% in patients with IPF in all 3 clinical trials

• TOMORROW (Study 1) showed a 68% relative reduction (-60 mL/year for OFEV [n=84] vs 191־ mL/year for placebo [n=83]), differences, 95% Cl=27, 235)

• INPULSIS-1 (Study 2) showed a 52% relative reduction (-115 mL/year for OFEV [n=309] vs 240־ mL/year for placebo [n=204]), difference=125, 95% Cl=78,173)

• INPULSIS2־ (Study 3) showed a 45% relative reduction (-114 mL/year for OFEV [n=329] vs -207 mL/year for placebo [n=219]), difference=94, 95% Cl=45,143)

- Significantly reduced the risk of time to first acute IPF exacerbation over 52 weeks compared with placebo in 2 out of 3 clinical trials1

• TOMORROW (investigator-reported): HR=0.16 (95% 01=0.04, 0.71)

• INPULSIS-1 (adjudicated): HR=0.55 (95% 01=0.20,1.54: not statistically significant)

• INPULSIS-2 (adjudicated): HR=0.20 (95% 01=0.07, 0.56)

INDICATION AND USAGE
OFEV is indicated for the treatment of idiopathic pulmonary fibrosis (IPF).

ONE CAPSULE, TWICE DAILY WITH FOOD
Not shown at actual size.

THE TOTALITY OF THE EVIDENCE DEMONSTRATES THAT OFEV SLOWS DISEASE PROGRESSION

To learn more about OFEV, please visit OFEV.com/formularykit

Boehringer Ingelheim

OFEV
(nintedanib)
capsules 150mg

Campaign files
Similar ads

Brand: Ofev
Country/Market: USA, North America
Target: Healthcare Professional (HCP)
Size/duration: Double-page spread
Publication/Aired:
Drug Topics - July 2015
Brand files